Damora Therapeutics, Inc. (DMRA)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

21.08 on 9 Oct 2026

1 buy4 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$209.84M

Free cash flow

$6.73M

Return on equity

-87.3%

Return on capital

-69.3%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
25 Sep 2026	Jarrett Jennifer Director, President and CEO	Bought	$252.88K	2.5%
6 Jul 2026	Winslow Garrett General Counsel	Sold at will	$7.35K	9.7%
2 Jan 2026	Schambye Hans T. Chief Executive Officer	Sold at will	$14.97K	13.0%
2 Jan 2026	Winslow Garrett General Counsel	Sold at will	$5.45K	12.1%
2 Jan 2026	Firmani Lori Chief Financial Officer	Sold at will	$2.89K	12.7%
3 Jul 2025	Schambye Hans T. Chief Executive Officer	Sold at will	$2.48K	15.5%

37out of 100

Profitability 0

Financial strength 70

Growth n/a

Insiders 52

Strongest on financial strength (70), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$252.88K

1 buy, 1 buyer

Sold

$30.65K

4 sales

Planned sales

under a 10b5-1 plan